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The Epstein-Barr virus (EBV) BamHI A mRNAs were originally identified in cDNA libraries from naso-
pharyngeal carcinoma, where they are expressed at high levels. The RNAs are differentially spliced to form
several open reading frames and also contain the BARF0 open reading frame at the 3* end. One cDNA, RK-
BARF0, included a potential endoplasmic reticulum-targeting signal peptide sequence. The RK-BARF0 protein
is shown here to interact with the Notch4 ligand binding domain, using yeast two-hybrid screening, coimmu-
noprecipitation, and confocal microscopy. This interaction induces translocation of a portion of the full-length
unprocessed Notch4 to the nucleus by using the Notch nuclear localization signal. These effects of RK-BARF0
on Notch intracellular location indicate that EBV possibly modulates Notch signaling. Unprocessed Notch4
was also detected in immunoprecipitated complexes from EBV-infected cells by using a rabbit antiserum raised
against a BARF0-specific peptide. This finding provides additional evidence for expression of RK-BARF0 and
its interaction with Notch during EBV infection. In EBV-infected, EBNA2-negative cells, RK-BARF0 induced
the expression of EBV latent membrane protein 1 (LMP1), and this induction was dependent on the RK-
BARF0/Notch interaction domain. The activation of LMP1 expression by RK-BARF0 may be responsible for
expression of LMP1 in EBV latent infections in the absence of EBNA2.
Epstein-Barr virus (EBV) is linked to the development of
several malignancies including endemic Burkitt’s lymphoma,
posttransplantation lymphoma, Hodgkin’s disease, and naso-
pharyngeal carcinoma (NPC) (35). Infection of B lymphocytes
with EBV in vitro results in immortalized lymphoblastoid cells
(23). Although virus is not produced in transformed lympho-
cytes, at least nine viral proteins, including six nuclear anti-
gens (EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C, and
EBNALP) and three membrane proteins (LMP1, LMP2A, and
LMP2B), are expressed (23). Molecular genetic analyses have
demonstrated that EBNA2, EBNA3A, EBNA3C, EBNALP,
and LMP1 are critical for in vitro B-lymphocyte transfor-
mation (5, 22, 27, 46), while EBNA3B, LMP2A, and LMP2B
are dispensable (26, 45). EBNA2 is the major regulator of viral
transcription and transactivates the expression of LMP1 (50),
in part through its interaction with the DNA binding protein,
RBP-Jk (CBF1) (14, 15, 19). RBP-Jk is a component of the
Notch signaling pathway and is activated through its interac-
tion with the intracellular cytoplasmic domain of Notch (9, 44).
These interactions convert RBP-Jk from a repressor of tran-
scription to an activator (18). EBNA2 seems to be a functional
homologue of activated Notch in EBV-infected cells.
EBV gene expression varies in infected tissue in the distinct
diseases and in different cell types. In NPC, most of the nuclear
antigens are not detected and only EBNA1, LMP1, and
LMP2A are consistently expressed (4, 7, 51). In addition, a
family of rightward transcripts from the BamHI A region was
originally identified in NPC, where they are abundantly and
consistently expressed (3, 12, 13, 16). Structural analysis of
clones obtained from a cDNA library of nude-mouse-passaged
NPC tumor, C15, revealed that the BamHI A transcripts are
differentially spliced, giving rise to a family of transcripts,
which are 39-end coterminal (37, 41). All of the transcripts
include the open reading frame (ORF) BamHI A rightward
frame 0 (BARF0) at their 39 ends, which is predicted to encode
a 174-amino-acid (aa) protein. Patients with NPC have anti-
bodies to the in vitro translation product of this ORF, suggest-
ing that the protein is expressed in vivo (13). Several additional
ORFs are formed by the distinct splices. One cDNA, RK-
BARF0, was obtained that extended the BARF0 ORF at the 59
end and would potentially encode a 279-aa protein (37).
The N terminus of RK-BARF0 protein contains a highly
hydrophobic region that resembles an endoplasmic reticulum
(ER)-targeting signal peptide sequence; however, other poten-
tial motifs were not identified. To clarify the function of the
RK-BARF0 protein, the yeast two-hybrid system was used
to identify cellular proteins that potentially interact with
RK-BARF0 in epithelial cells. Using an epithelial cell-spe-
cific cDNA library, the RK-BARF0 protein was found to in-
teract with extracellular domain of the Notch family proteins
Notch3 and Notch4.
Notch defines a family of transmembrane receptor proteins
found in a variety of organisms including mammals (43). Notch
is synthesized in the ER and further processed in the trans-
Golgi network (TGN) to produce two fragments, which are
then linked through disulfide bonds and transported to the
plasma membrane (2, 34). The amino-terminal fragment is the
extracellular subunit and contains multiple epidermal growth
factor (EGF)-like repeats. Through direct contact with a cell
that expresses a Notch ligand, such as Delta or Jagged, the
cytoplasmic domain of Notch is proteolytically cleaved and
released from the plasma membrane (38, 42). The cleaved
form of Notch is then thought to interact with modulators and
effectors of Notch signaling such as Deltex and the RBP-Jk
transcription factor, the mammalian homologue of the Dro-
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sophila Suppressor of Hairless protein (18). The relative abun-
dance, subcellular location, and intermolecular interactions of
Notch all contribute to the multiplicity of effects of Notch
signaling. This study evaluates the effects of the RK-BARF0/
Notch interaction on Notch and on viral gene expression.
MATERIALS AND METHODS
Plasmid construction. The GAL4 DNA binding domain (GAL4BD) fusions
with RK-BARF0 and deletion mutants were constructed in vector pAS2-1 (Clon-
tech) by PCR amplification of the RK-BARF0 cDNA fragments encoding aa 12
to 279, 119 to 279, 12 to 128, 12 to 158, 12 to 179, 12 to 209 and 12 to 249 of RK-
BARF0, followed by cloning into the NdeI-SalI or NdeI-SmaI sites of pAS2-1
to produce pASRK12–279, pASRK119–279, pASRK12–128, pASRK12–158,
pASRK12–179, pASRK12–209, pASRK12–249, respectively. To express RK-
BARF0 and its C-terminally truncated mutants with epitope tags, pRK-BARF0,
pRK1–179, and pRK1–158 were amplified by PCR from the RK-BARF0 cDNA
fragment, encoding aa 1 to 279, 1 to 179, or 1 to 158 of RK-BARF0 with FLAG
and six-histidine (FLAG/His6) epitope tags in the carboxy terminus, respective-
ly, and subcloned into the blunt-ended HindIII site of pMEP4 (Invitrogen).
pBARF0 was constructed by PCR amplification of pRK-BARF0, encoding aa
106 to 279 of RK-BARF0 with a C-terminal FLAG epitope tag, and was also
subcloned into pMEP4.
pNot4 containing full-length human Notch4 cDNA was constructed by fusing
four clones from the human lung MATCHMAKER cDNA library (Clontech)
and a DNA fragment, containing nucleotides 3011 to 6033 of Notch4 cDNA
(kindly provided by K. Sugaya, National Institute of Radiological Sciences,
Chiba, Japan). To express Notch4 protein with three myc epitope tags at the C
terminus (Notch4-myc), pNot4M3 was constructed by PCR amplification of
pNot4 and subcloning into pA3M (1), encoding three iterated copies of the myc
epitope. To express intracellular functional domains of truncated Notch4 protein
(TMNotch4) which is lacking the region of Notch4 from aa 1559 to 2010, two
DNA fragments, including nt 1 to 3776 and 3770 to 4675, were isolated by
EcoRI-ScaI digestion of pNot4 and PCR amplification of pNot4, respectively.
These DNA fragments were subcloned into EcoRI-XbaI sites of pA3M to yield
pNot4TM. An inducible Notch4 expression plasmid was synthesized by transfer-
ring an EcoRI-XbaI fragment from the myc-tagged Notch4 gene from pNot4M3
into the HindIII site of pMEP4 to yield pNot4(M). All of the DNA constructs
were sequenced at the University of North Carolina—Chapel Hill (UNC) Au-
tomated DNA Sequencing Facility on a model 377 DNA Sequencer (Perkin-
Elmer, Applied Biosystems Division).
Yeast two-hybrid screening and analysis. Yeast transformation was performed
by the method of Gietz et al. (11). The yeast strain Y190 (Clontech) was
transformed with pASRK12-279, and transformants were plated on Trp2 selec-
tion medium. GAL4BD-RK12-297 fusion protein expression was verified in
single colonies by immunoblotting using the GAL4 DNA-BD antibody (Clon-
tech). The pASRK12-279 transformant was subsequently transformed with the
human lung MATCHMAKER cDNA library, and selection was done on Trp2
Leu2 His2 selection medium in the presence of 25 mM 3-aminotriazole (Sigma).
Colonies with moderate to intense growth were tested for b-galactosidase (b-gal)
expression.
To verify the interaction of these clones with RK12-279, positive colonies were
plated on Leu2 selection medium containing 10 mg of cycloheximide per ml to
lose pASRK12-279, and Y190 cells carrying only library-derived plasmid were
mated with the Y187 transformant with pAS2–1, pASRK12–128, or pASRK119–
279. Library-derived plasmids were recovered by transformation of competent
DH5a cells with total DNA preparations from Y190 cells followed by selection
for ampicillin resistance. To identify the interaction domain of RK-BARF0 with
the cDNA clone from yeast two-hybrid screening, Y190 was transformed with
pASRK12–128, pASRK12– 158, pASRK12–179, pASRK12–209, pASRK12–249,
and pASRK12–279 and mated with library-derived plasmid-transformed Y187.
Mated yeast cells were plated on Trp2 Leu2 His2 selection medium containing
25 mM 3-aminotriatole and tested for b-gal expression.
Cell culture and transfection. The H1299 cell line, derived from a human
non-small-cell lung carcinoma, was maintained in Dulbecco’s modified Eagle’s
medium containing penicillin and streptomycin and supplemented with 10%
fetal bovine serum (Gibco BRL). To obtain H1299 cells expressing FLAG/His6
epitope-tagged RK-BARF0, RK1–179, RK1–158, BARF0, or pMEP4 and myc
epitope-tagged Notch4 or pA3M, the DNA constructs were transfected using
Lipofectin (Gibco BRL). To obtain stably expressing cell lines, transfected
H1299 cells were selected in the presence of 200 mg of hygromycin B (Boehr-
inger) per ml and 600 mg of G418 (Gibco BRL) per ml. BJAB and P3HR1 cell
lines, derived from EBV-negative and -positive Burkitt’s lymphoma, respectively,
were maintained in RPMI 1640 medium containing penicillin and streptomycin
and supplemented with 10% fetal bovine serum. Stable DG75 and Raji cell lines
containing the inducible myc epitope-tagged Notch4 or pMEP4 and stable
P3HR-1 cell lines containing the inducible FLAG/His6 epitope-tagged RK-
BARF0, RK1–179, RK1–158, or pMEP4 were produced after electroporation
and selection in the presence of 200 mg of hygromycin B.
Coimmunoprecipitation of RK-BARF0 and Notch4 from H1299 epithelial
cells. H1299 cells (5 3 105) were transiently transfected with 2.5 mg of FLAG/
His6 epitope-tagged RK-BARF0, RK1–179, RK1–158, or pMEP4 and 2.5 mg of
myc epitope-tagged Notch4 or pA3M plasmids and induced by addition of 5 mM
of CdCl2 approximately 24 h after transfection. The cells were scraped from
tissue culture dishes at 16 h postinduction and lysed for 30 min on ice in lysis
buffer (20 mM Tris-HCl [pH 7.8], 150 mM NaCl, 1 mM EDTA, 10% glycerol,
0.5% 3-[(3-cholamidopropyl)-dimethylammonia]-1-propanesulfonate [CHAPS])
containing 1 mM phenylmethylsulfonyl fluoride (PMSF), 0.5 mM sodium
orthovanadate, and 5 mg of aprotinin per ml. Cell lysates were clarified by
centrifugation. The myc epitope-tagged Notch4 or FLAG/His6 epitope-tagged
RK-BARF0 were immunoprecipitated with anti-FLAG M2 monoclonal anti-
body-conjugated beads (Sigma) or anti-myc monoclonal antibody-conjugated
beads (Santa Cruz) for 8 h at 4°C. The beads were then washed, and protein
complexes were recovered by boiling in sodium dodecyl sulfate (SDS) sample
buffer. Protein samples were subjected to SDS-polyacrylamide gel electrophore-
sis (PAGE), and transferred to Immobilon-P (Millipore). Anti-OctA-probe poly-
clonal antibody (Santa Cruz) was used at 0.5 mg per ml for the detection of
FLAG/His6 epitope-tagged RK-BARF0, RK1–179 or RK1–158. Anti-myc probe
polyclonal antibody (Santa Cruz) was used at 0.5 mg per ml for the detection of
myc epitope-tagged Notch4. Horseradish peroxidase-conjugated goat anti-rabbit
antibody (Amersham) was used at a 1:2,000 dilution as the secondary antibody to
detect bound primary antibody. Reactive proteins were detected by incubation of
washed filters in SuperSignal substrate (Pierce) followed by exposure to X-ray
film (Kodak).
Coimmunoprecipitation of Notch4 from Burkitt’s lymphoma cell lines using
rabbit antiserum raised against an RK-BARF0 peptide. DG75 and Raji cell lines
containing the inducible myc epitope-tagged Notch4 or pMEP4 were induced by
addition of 5 mM CdCl2 approximately 36 h after plating. The cell lysates were
prepared as described above and were immunoprecipitated using an affinity-
purified rabbit antiserum raised against a BARF0-specific peptide and Gamma-
bind Sepharose beads (Pharmacia). The beads were washed, and protein com-
plexes were recovered by boiling in SDS sample buffer. To detect the myc-tagged
Notch4, the protein samples were subjected to SDS-PAGE, transferred to Im-
mobilon-P, and reacted with anti-myc epitope monoclonal antibody 9E10 (Santa
Cruz) at 0.5 mg per ml.
Immunofluorescence analyses. H1299 cells containing inducible FLAG/His6
epitope-tagged RK-BARF0, RK1–179, or RK1–158 and/or myc epitope-tagged
Notch4 were induced and analyzed 24 h postinduction. The cells were fixed with
50% methanol–50% acetone at 220°C and incubated with 10 mg of anti-FLAG
M2 monoclonal antibody per ml and 0.7 mg of anti-myc polyclonal rabbit
antibody per ml. The cells were washed and incubated with fluorescein isothio-
cyanate-conjugated goat anti-mouse antibody (Jackson ImmunoResearch Labo-
ratories) (1:200 dilution) and Lissamine rhodamine-conjugated (LSRC) goat
anti-rabbit antibody (Jackson) (1:300 dilution). The cells were washed, mounted
with VECTASHIELD mounting medium (Vector), and visualized with a Zeiss
Axioplan fluorescence microscope. Confocal microscopy was performed with a
Zeiss confocal microscopy system in the UNC Research Microscopy Laboratory.
Confocal fluorescence images were collected and translated to TIFF format
using NIH Image, and composite figures were created using Adobe Photoshop
5.0.2.
Preparation of nuclear lysate. Stable H1299 clones (2 3 106) containing
FLAG/His6 epitope-tagged RK-BARF0 or pMEP4 were plated, transiently
transfected with 10 mg of myc-tagged Notch4-expressing plasmids using Lipo-
fectin, and induced with 5 mM CdCl2 approximately 24 h after transfection. To
purify the nucleus, the cells were lysed at 24 h postinduction in hypotonic lysis
buffer (10 mM Tris-HCl [pH 7.8], 10 mM NaCl, 3 mM MgCl2, 0.5% NP-40)
containing 5 mg of aprotinin per ml. Nuclei were isolated by centrifugation at
1,500 3 g for 5 min at 4°C and lysed for 30 min on ice in solubilization buffer (10
mM Tris-HCl [pH 7.8], 150 mM NaCl, 1 mM EDTA, 0.5% SDS, 0.1% sodium
deoxycholate, 1% NP-40) containing 1 mM PMSF and 5 mg of aprotinin per ml.
To make whole-cell lysates, the cells were lysed in solubilization buffer. The
protein concentrations of nuclear and whole-cell lysates were quantitated using
the DC protein assay reagent (Bio-Rad). Equivalent amounts of protein were
analyzed by immunoblotting for Notch4-myc, using 1 mg of monoclonal antibody
9E10 per ml, and detected with horseradish peroxidase-conjugated goat anti-
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mouse antibody (Amersham). Reactive proteins were detected by incubation of
washed filers in SuperSignal substrate followed by exposure to X-ray film.
Analysis of LMP1 induction and RK-BARF0 secretion in P3HR1. Stable
P3HR1 cell lines (107) containing FLAG/His6 epitope-tagged RK-BARF0,
RK1–179, RK1–158, or pMEP4 were plated and induced by addition of 1.5 mM
CdCl2. The cells were collected by centrifugation from tissue culture flasks at
48 h postinduction and lysed for 30 min on ice in RIPA buffer (20 mM Tris-HCl
[pH 7.8], 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.2% SDS, 0.2% sodium
deoxycholate) containing 1 mM PMSF, 0.5 mM sodium orthovanadate, and 5 mg
of aprotinin per ml. Cell lysates were subjected to SDS-PAGE and transferred to
Immobilon-P. RK-BARF0, RK1–179, and RK1–158 were detected with an anti-
His probe at 0.5 mg per ml. LMP1 expression was detected by CS1-4 (DAKO) at
a 1:200 dilution. The culture medium was recentrifuged at 3,000 3 g for 30 min
to remove debris. Supernatants were recovered and incubated with anti-FLAG
M2 beads for 8 h at 4°C. The beads were then washed with lysis buffer, and
protein complexes were recovered by boiling in SDS sample buffer. Protein
samples were subjected to SDS-PAGE and transferred to Immobilon-P. Anti-
His-probe polyclonal antibody (Santa Cruz Biotechnology) was used at 0.5 mg
per ml for the detection of FLAG/His6 epitope-tagged RK-BARF0, RK1–179,
and RK1–158.
RESULTS
A yeast two-hybrid screen reveals that the extracellular re-
gions of Notch3 and Notch4 interact with a predicted hydro-
phobic helix domain of RK-BARF0. The RK-BARF0 protein
contains a signal peptide-like sequence at its N terminus; how-
ever, other regions of similarity to known proteins were not
identified (37). To further analyze the function of RK-BARF0,
the yeast two-hybrid system was used to identify cellular pro-
teins that interact with RK-BARF0. The highly hydrophobic
region at the N terminus was deleted, and the DNA encoding
aa 12 to 279 was fused in frame to the GAL4 DNA binding do-
main (GAL4BD). The GAL4-activating domain (GAL4AD)
was fused to a human lung cDNA library. Approximately 8.5 3
105 transformants were tested for growth on selection medium.
Sequence analysis of two positive clones, c36-1 and c41-2, re-
vealed that the cDNAs represented the extracellular domains
of human Notch3 and Notch4, respectively (Fig. 1A). The
extracellular region of Notch proteins has multiple EGF-like
repeats, and Notch3 and Notch4 contain 34 and 29 repeats,
respectively (48). Other protein-interacting domains of Notch,
including the RAM domain and the Notch or ankyrin repeats,
were not contained in the c36-1 and c41-2 clones, suggesting
that RK-BARF0 must interact with Notch through the EGF-
like repeat elements.
To verify these interactions between RK-BARF0 and the
two Notch clones, yeast Y190 cells containing the c41-2/
GAL4AD fusion were mated with Y187 transformants carry-
ing pAS2-1, encoding GAL4BD only, pASRK12–128, encod-
ing the amino-terminal 12 to 128 aa of RK-BARF0 fused to
GAL4BD, or pASRK119–279, encoding the carboxy terminal
119 to 279 aa of RK-BARF0 fused to GAL4BD. After mating,
the yeast cells were plated on selective medium. Only yeast
containing pASRK119–279, representing the carboxy terminus
of RK-BARF0, could grow in the absence of histidine and also
had high levels of b-gal activity (data not shown). These re-
sults revealed that aa 119 to 279 of RK-BARF0 interact
with Notch4. To further define the Notch interaction domain
of RK-BARF0, five C-terminal deletion constructs of RK-
BARF0 fused to GAL4BD were tested for Notch4 interaction
by mating and yeast two-hybrid analysis (Fig. 1B). The yeast
strains carrying RK12–279, RK12–249, RK12–209, and RK12–
179 could grow on the selective medium with moderate to high
levels of b-gal activity, while the deletion constructs represent-
ing the amino terminus, RK12–128 and RK12–158 could not
grow on selective media (Fig. 1B and 1C). Similar results were
obtained from mating analyses with these mutants using yeast
strains carrying human Notch3 clone c36-1 (data not shown).
This analysis indicated that the region of RK-BARF0 between
aa 159 and 179 is necessary for interaction with Notch. The
hydrophobicity plot by Kyte-Doolittle analysis (25) and poten-
tial secondary structure predicted by 3D-1D compatibility al-
gorithm (21) indicated that the region between aa 159 and 179
of RK-BARF0 has a hydrophobic helical structure, suggesting
that RK-BARF0 interacts with the extracellular region of
Notch protein through a hydrophobic helix (Fig. 1D and E).
RK-BARF0 associates with Notch4 in vivo. To examine the
interaction of RK-BARF0 and Notch4 in vivo, a full-length
Notch4 cDNA was synthesized and cloned in frame into a
pA3M, which is a pcDNA3 plasmid containing three repeated
c-myc epitopes at the carboxy terminus under the control of
the human cytomegalovirus immediate-early promoter. Three
RK-BARF0 constructs, RK-BARF0 (aa 1 to 279), RK1–179,
and RK1–158, containing FLAG/His6 epitopes at the C ter-
minus, were also prepared and cloned into pMEP4, which
contains the inducible human metallothionein promoter. We
have consistently achieved excellent protein expression in ep-
ithelial cells by using the metallothionein promoter, which
enables expression of potentially toxic proteins in cell lines.
The Notch4 and RK-BARF0 plasmids were transfected into
the human epithelial cell line, H1299. After induction with
CdCl2, lysates were prepared and complexes containing RK-
BARF0 were immunoprecipitated using the anti-FLAG M2
monoclonal antibody. Western blot analyses of the immuno-
precipitated complexes indicated that RK-BARF0 and the C-
terminal deletion mutant, RK1–158, were expressed at similar
levels, with somewhat lower expression of RK1–179 (Fig. 2A).
Although equivalent amounts of transfected Notch4 were de-
tected in the total-cell lysates, immunoblotting with an anti-
myc polyclonal antibody to identify myc epitope-tagged Notch4
(Notch4-myc) detected Notch4 in precipitated complexes con-
taining RK-BARF0 and RK1–179 but not RK1–158 (Fig. 2B
and C). This observation is consistent with the results of yeast
two-hybrid analysis and indicated that aa 159 to 179 of RK-
BARF0 are also necessary for the interaction between RK-
BARF0 and Notch in vivo. Interestingly, the unprocessed full-
length form of Notch4 and also the intracellular C-terminal,
processed form of Notch4, which lacks the EGF-like repeats,
were detected in complexes with both RK-BARF0 and RK1–
179. The presence of the intracellular fragment of processed
Notch in the precipitated RK-BARF0 complexes indicates that
RK-BARF0 also interacts with processed Notch4 containing
both the extracellular and intracellular subfragments, joined by
cysteine bonds. These bonds are denatured during SDS-PAGE
such that only the intracellular Notch fragment which contains
the myc epitope is detected by Western blotting. Comparison
of the amount of Notch4 present in the total-cell lysate with
that detected in the RK-BARF0 containing complexes indi-
cated that approximately 15% of the transfected Notch4 was
present in the complexes. However, RK-BARF0 also interacts
with Notch1 (data not shown). This interaction with endog-
enously expressed Notch1 would decrease the amount avail-
able for interaction with transfected Notch4.
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The interaction of Notch4 with RK-BARF0 was confirmed
in the reciprocal immunoprecipitation. Immunoblot analysis of
the immunoprecipitated Notch4-containing complexes de-
tected equivalent amounts of Notch4 in the complexes (Fig.
2D). Using an anti-His polyclonal antibody, immunoblots of
the total-cell lysates indicated that RK-BARF0 and RK1–179
were expressed at equal levels and that there was a somewhat
greater expression of RK1–158 (Fig. 2E). In agreement with
the data presented above, only RK-BARF0 and RK1–179 were
detected in the Notch4-containing immunoprecipitated com-
plexes (Fig. 2F).
It is known that Notch has a signal sequence in the N ter-
minus, is synthesized in the ER, and is processed in the TGN
(2). Since the RK-BARF0 protein also has a signal peptide-like
sequence at its amino terminus, it is likely to also be synthe-
sized in the ER. The interaction of RK-BARF0 with unproc-
essed Notch suggests that the RK-BARF0/Notch interaction
occurs in the ER prior to Notch processing. The BARF0 ORF,
which is present at the 39 end of all of the variably spliced
BamHI A transcripts, lacks the N-terminal hydrophobic se-
quence of RK-BARF0 and contains aa 106 to 279 of RK-
BARF0, including the Notch-interacting domain. BARF0,
tagged with the FLAG epitope, was cloned into the pMEP4
vector, and RK-BARF0 and BARF0 were transfected with
Notch4-myc into H1299 cells. After induction of expression
and precipitation, immunoblot analysis indicated that both
RK-BARF0 and BARF0 were present in the precipitated com-
plexes (Fig. 3A). Notch4 was expressed at equivalent levels in
FIG. 2. RK-BARF0 associates with processed and unprocessed forms of Notch4 in vivo. H1299 cells (5 3 105) were transiently transfected with
both FLAG/His6-tagged RK-BARF0 (aa 1 to 279), RK1–179, RK1–158, or pMEP4 and Notch4myc or pA3M. RK-BARF0, RK1–179, and
RK1–158 were induced with 5 mM CdCl2 for 16 h, immunoprecipitated, and analyzed on immunoblots. (A) Immunoblot with an anti-FLAG
antibody to identify RK-BARF0, RK1–179, and RK1–158 in the immunoprecipitated RK-BARF0 complexes. (B) Immunoblot analysis with
anti-myc antibody to identify Notch4 expression in the transfected cells. (C) Identification of processed and unprocessed forms of Notch4 in the
immunoprecipitated (IP) RK-BARF0 complexes using anti-myc epitope polyclonal antibodies. (D) Immunoblot with anti-myc antibody to identify
Notch4 in the immunoprecipitated Notch4 complexes. (E) Immunoblot analysis with antihistidine antiserum to determine the expression of
RK-BARF0, RK1–179, and RK1–158 in the transfected cells. (F) Detection of RK-BARF0 and RK1–179, using antihistidine antibody in the
Notch4 complexes immunoprecipitated with anti-myc antibody.
388 KUSANO AND RAAB-TRAUB J. VIROL.
each of the transfections (Fig. 3B). The processed form of
Notch4 was present in the immunoprecipitated complexes with
BARF0, but only trace levels of unprocessed Notch were
present, comparable to that detected in precipitates prepared
from cells containing the pMEP4 vector control (Fig. 3C). This
observation indicates that the potential protein product of the
BARF0 ORF also can interact with Notch and suggests that
the N-terminal hydrophobic region of RK-BARF0 is necessary
for the interaction with unprocessed Notch4.
RK-BARF0 induces the translocation of unprocessed
Notch4 to the nucleus. To further analyze the interaction be-
tween RK-BARF0 and Notch4, the intracellular location of
RK-BARF0 and Notch was determined. Stable cell lines con-
taining Notch4 and the FLAG/His6-tagged RK-BARF0 and
deletion mutants in H1299 cells were prepared and analyzed
for protein expression and intracellular location by using the
anti-FLAG M2 monoclonal antibody and a fluorescein-conju-
gated anti-mouse secondary antibody to detect RK-BARF0.
RK-BARF0 and RK1–179 were predominantly found in a
punctate staining pattern throughout the nucleus and in the
perinuclear region, possibly representing the ER (Fig. 4A).
RK-BARF0 was also mainly detected in the nuclear pellet of
biochemically fractionated RK-BARF0-expressing H1299 cells
(data not shown). However RK1–158, which does not interact
with Notch4 protein, was localized throughout the cytoplasm
(Fig. 4A). These data indicate that the region of RK-BARF0
which is required for the interaction with Notch protein is also
necessary for the nuclear localization of RK-BARF0.
To determine if the interaction with RK-BARF0 affected
Notch localization, stable H1299 cell lines expressing the
Notch4 protein alone or in the presence of RK-BARF0 were
analyzed. In the absence of RK-BARF0, the Notch4-myc pro-
tein was found throughout the cytoplasm, with no staining of
the nucleus (Fig. 4B, Notch4 with Vector). In contrast, in the
presence of RK-BARF0, Notch4 was detected in the nucleus
and perinuclear region (Fig. 4B, Notch4 with RK-BARF0).
When Notch4 was coexpressed with the RK1–158 deletion
mutant of RK-BARF0 which cannot interact with Notch,
Notch4 remained in the cytoplasm (Fig. 4B, Notch4 with RK1–
158). These data suggest that the interaction of RK-BARF0
with Notch4 protein induces the nuclear localization of Notch4.
The staining for RK-BARF0 and Notch4 in the same cell in
Fig. 4A, RK-BARF0 with Notch4, and Fig. 4B, Notch4 with
RK-BARF0, suggested colocalization. The interaction and co-
localization of RK-BARF0 and Notch4 in the nucleus were
confirmed using confocal microscopy. RK-BARF0 and Notch4
protein were detected in punctate nuclear granules using flu-
orescein-conjugated secondary antiserum for detection of RK-
BARF0 and rhodamine-conjugated secondary antiserum for
detection of Notch4. The colocalized proteins are indicated in
yellow (Fig. 4C). The cell and nuclear shape were revealed by
differential interference contrast microscopy (Fig. 4C).
RK-BARF0 does not have a potential nuclear localization
signal (NLS), and the deletion mutant of RK-BARF0 that
lacks the Notch-interacting region does not translocate to the
nucleus. However, an NLS is present in the intracellular por-
tion of Notch4, and forms of Notch that lack the extracellular
domain localize to the nucleus (1, 42). To determine if the
localization of RK-BARF0 and Notch in the nucleus is depen-
dent on the Notch NLS, a deleted form of Notch contain-
ing the extracellular domain and transmembrane region and
lacking the entire intracellular region containing the NLS
(TMNotch4) was coexpressed with RK-BARF0 (Fig. 4D).
RK-BARF0 (Fig. 4D, RK-BARF0 with TMNotch4) and
TMNotch4 (Fig. 4D, TMNotch4 with RK-BARF0) were both
detected in the cytoplasm. These data indicate that the trans-
location of the RK-BARF0/Notch complex to the nucleus is
dependent on the Notch NLS. The interaction of RK-BARF0
with the Notch extracellular domain apparently affects the
tertiary structure of Notch such that the Notch/RK-BARF0
complex is transported to the nucleus through the Notch NLS.
The translocation of Notch4 protein to the nucleus was also
FIG. 3 BARF0 interacts with processed Notch. (A) Immunoblot of RK-BARF0 or BARF0 (aa 106 to 279) after induction and immunopre-
cipitation (IP) with an anti-FLAG polyclonal antibody. (B) Immunoblot analysis of whole cell lysates to identify Notch4 expression after
transfection. (C) Identification of processed and unprocessed forms of Notch4 in the RK-BARF0 and BARF0 immunoprecipitated complexes.
WB, Western blot.
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FIG. 4. RK-BARF0 Colocalizes with Notch4 in the nucleus. (A) Cell lines containing both Notch4-myc and FLAG/His6-tagged RK-BARF0,
RK1–179, RK1–158 or pMEP4 expression plasmids were induced and stained using a monoclonal antibody to FLAG and FITC-conjugated
anti-mouse immunoglobulin G (IgG) to identify RK-BARF0. (B) Cell lines containing Notch4-myc or both Notch4-myc and FLAG/His6-tagged
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examined by transfection of Notch4 into the H1299 cell line
containing RK-BARF0 in the pMEP4 inducible-expression
plasmid. Analysis of the whole-cell lysates detected equivalent
expression of unprocessed Notch4 in whole-cell lysates from
the transfected cell lines with or without induction of the
pMEP4 promoter (Fig. 5A). The presence of transfected
Notch4 in the nuclear fraction was determined before and after
induction of RK-BARF0 expression. Unprocessed Notch4 was
not detected in equivalent amounts of nuclear lysate from cells
that contained the pMEP4 vector or in cells that contained
RK-BARF0 without induction. However, after induction of
RK-BARF0 expression, a portion of unprocessed Notch4 was
detected in the nuclear fraction (Fig. 5B). The amount of
Notch4 detected in 7 mg of nuclear protein after induction of
RK-BARF0 expression was two- to threefold greater than that
detected in 23 mg of nuclear protein from the vector-contain-
ing cells. The detection of unprocessed Notch4 in the nuclear
fraction only after induction of RK-BARF0 expression con-
firmed that the nuclear localization of the unprocessed form of
Notch protein is dependent on of RK-BARF0.
RK-BARF0 has an ER-targeting signal and can be secreted.
The interaction of RK-BARF0 with unprocessed Notch sug-
gests that the amino-terminal hydrophobic region of RK-
BARF0 is indeed an ER-targeting sequence and that RK-
BARF0 and Notch are synthesized and interact in the ER prior
to Notch processing in the Golgi. In H1299 cells, 2 h after
induction, RK-BARF0 was detected in the perinuclear region,
characteristic of the ER, and by 4 h after induction, RK-
BARF0 was present in the nucleus in some cells (Fig. 6A).
A signal peptide sequence not only suggests that RK-
BARF0 is targeted to the ER but also suggests that RK-
BARF0 could be processed and secreted into the medium. To
determine if RK-BARF0 can be secreted, cell lines stably ex-
pressing RK-BARF0, RK1–179, and RK1–158 were estab-
lished in the P3HR1 cell line, which expresses a very low level
of endogenous Notch1. The full-length proteins were detected
in the whole-cell lysates; however, RK1–158, which does not
interact with Notch, and a smaller form, probably representing
RK1–158, after cleavage of the signal peptide, were abundant
in the culture medium (Fig. 6B). RK1–179 and its cleaved form
were also clearly evident; however, only trace levels of RK-
BARF0 and a smaller form were detected. These data suggest
that RK-BARF0 can be processed and secreted. The greatly
increased secretion of RK1–158, which does not interact with
Notch and does not translocate to the nucleus, suggests that
the interaction with Notch may inhibit the secretion of RK-
BARF0.
RK-BARF0 induces LMP1 expression in EBNA2-negative
P3HR1 cells. EBNA2 is the major viral transactivator of ex-
pression of the EBV oncogene LMP1. Transactivation of
LMP1 by EBNA2 is complex; however, it is partially mediated
through its interaction with RBP-Jk. Interestingly, in EBV-
infected NPC, LMP1 is expressed in the absence of EBNA2.
P3HR1 is an EBV-positive Burkitt’s lymphoma cell line in
which the EBNA2-encoding region is deleted, and it expresses
very low levels of LMP1. To determine if the RK-BARF0/
Notch interaction positively affects expression of LMP1 in the
absence of EBNA2, stable cell lines containing RK-BARF0
and the noninteracting deletion, RK1–158, were derived from
P3HR1 cells and analyzed for LMP1 expression. After induc-
tion of expression of RK-BARF0 in P3HR1 cells, the amount
of LMP1 was considerably increased in comparison with that in
P3HR1 cells expressing RK1–158, the mutant that does not
interact with Notch, or the vector control, pMEP4 (Fig. 7).
These results indicate that RK-BARF0 can activate LMP1
expression in an EBNA2-independent manner through the
Notch interaction domain.
Coimmunoprecipitation of RK-BARF0 and Notch4 from the
EBV-infected Raji cell line. We have previously produced a
rabbit antiserum to a BARF0-specific peptide representing aa
115 to 132 of RK-BARF0 (10). This antiserum specificially
reacts with a glutathione transferase-BARF0 fusion protein, in
vitro-translated BARF0, and transfected RK-BARF0 (10).
The antiserum also cross-reacts with a cellular protein that is
abundant in DG75 and other EBV-negative Burkitt’s lym-
phoma cells (24). This protein has since been identified as
major histocompatibility complex (MHC) class II (T. Sculley,
personal communication). Since expression of class II is in-
duced by EBV infection and the estimated molecular weight of
RK-BARF0 is the same as that of MHC class II, the detection
of endogenously expressed RK-BARF0 using this reagent is
obscured. To use the RK-BARF0/Notch interaction to assess
the expression of RK-BARF0 expression in EBV-infected
cells, stable cell lines containing myc-tagged Notch4 in pMEP4
were established from the EBV-positive cell line Raji and the
EBV-negative cell line DG75. Expression of Notch 4 was in-
duced by treatment with 5 mM CdCl2 for 36 h prior to prep-
aration of cell lysates. Immunoblot analysis indicated that
Notch4 expression was induced in both cell lines with increased
expression in DG75 cells (Fig. 8A). The RK-BARF0 antiserum
was enriched by affinity purification with the BARF0 specific
peptide and used for immunoprecipitation from the Notch4-
expressing Raji and DG75 cells. Immunoblot analysis using the
anti-myc monoclonal antibody detected Notch4 in the immu-
noprecipitated complexes from Raji cells but not from DG75,
despite the higher level of Notch4 expression in these cells
(Fig. 8B). In addition, Notch4 was not detected after immu-
noprecipitation of MHC class II from induced Raji or DG75
cells (data not shown). Immunoprecipitation of unprocessed
Notch4 from the EBV-infected Raji cell line, using the
BARF0-specific antibody, provides indirect evidence that the
RK-BARF0 protein is expressed in EBV-positive Raji cells.
RK-BARF0, RK1–158, or the pMEP4 vector were stained with anti-myc polyclonal antibody and LSRC-conjugated anti-rabbit IgG to identify
Notch4. (C) A stable cell line containing Notch4-myc and FLAG/His6-tagged RK-BARF0 was stained with anti-FLAG M2 monoclonal antibody
and anti-myc polyclonal antibody using FITC-conjugated anti-mouse IgG to detect RK-BARF0 and RISC-conjugated anti-rabbit IgG to detect
Notch4. Confocal images were collected, and composite figures were created using Adobe Photoshop 5.0.2. The differential interference contrast
microscopy image of the cell is presented. (D) A cell line containing the extracellular to transmembrane region of Notch4 (TMNotch4)-myc in
pA3M and FLAG/His6-tagged RK-BARF0 was stained with a monoclonal FLAG and FITC-conjugated anti-mouse IgG to identify RK-BARF0
and anti-myc polyclonal antibody and LSRC-conjugated anti-rabbit IgG to identify TMNotch4.
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DISCUSSION
Notch4 (also called Int3) is a member of the Notch receptor
family and is thought to be involved in endothelial and epithe-
lial differentiation in mammals (48, 49). Notch was originally
identified as a Drosophila neurogenic gene required for correct
segregation of epidermal cells from neuronal cell precursors
during embryogenesis, but subsequent studies demonstrated
that Notch is widely expressed during embryonic and adult
development and mediates many cell-cell interactions during
fly development (8). Notch directly activates gene expression
through its interaction with the DNA binding protein RBP-Jk,
the mammalian homologue of the Drosophila Suppressor of
Hairless protein. The major transcriptional regulator of EBV
during latent infection in B lymphocytes, EBNA2, also directly
interacts with RBP-Jk in a manner analogous to that of Notch
and activates cellular and viral promoters through RBP-Jk (14,
15, 19). The activated form of mouse Notch1 can substitute for
EBNA2 and can transactivate the EBV LMP1 promoter (17).
The interaction of RBP-Jk with EBNA2 is apparently carefully
regulated and is thought to be affected by at least three other
EBV proteins, EBNA3A, EBNA3B, and EBNA3C, which also
interact with RBP-Jk and possibly negatively regulate EBNA2-
mediated transactivation (36, 52).
The data presented here indicate that the potential EBV
protein, RK-BARF0, interacts with the Notch in the ER prior
to processing in the TGN. The biogenesis of Notch is complex,
with expression in the ER, processing in the TGN, and cleav-
age at the plasma membrane to release the cytoplasmic frag-
ment, which activates cellular gene expression through its in-
teraction with RBP-Jk (18). The interaction of RK-BARF0
with the Notch ligand binding domain apparently unmasks the
Notch NLS and induces translocation of unprocessed Notch to
the nucleus. This interaction also results in a decrease in the
levels of total Notch (data not shown). These effects on Notch
may inhibit Notch activation and signaling and also reduce the
amount of RBP-Jk that is bound to Notch. This effect might
facilitate the interaction of EBNA2 with RBP-Jk to activate
the expression of LMP1.
However, in most of the malignancies associated with EBV,
including NPC, LMP1 is expressed in the absence of EBNA2
(35). The BamHI A RNAs are abundantly expressed in NPC
and were originally identified in cDNA libraries from NPC
RNA (12, 16). The levels of these RNAs are considerably
lower in transformed lymphocytes, and it is difficult to detect
the mRNAs on Northern blots (12, 37). The difference in the
relative abundance of the RNAs may indicate that the proteins
potentially encoded by these RNAs are predominantly ex-
pressed and function in infections where the EBNA2 and
EBNA3 proteins are not expressed.
The data presented here indicate that the RK-BARF0/Notch
interaction can induce the expression of LMP1 in the absence
of EBNA2. The regulation of LMP1 expression is complex,
and EBNA2-dependent and -independent elements have been
identified (47). An ATF/CRE element in the promoter medi-
ates EBNA2-independent activation of the LMP1 promot-
er and binds ATF1, ATF2, and c-Jun (39). The Notch/RK-
BARF0 interaction may activate LMP1 expression through
effects on RBP-Jk or through other pathways affected by
Notch. Notch interacts with the cytoplasmic protein Deltex,
which inhibits activation of the c-Jun terminal kinase (JNK),
and recent studies also implicate Notch in activation of NF-kB
p50-containing complexes (6, 28–30, 32, 33). Notch can also
affect gene expression independently of its interaction with
RBP-Jk. Dominant negative forms of RBP-Jk do not block the
effects of Notch on myogenic differentiation of C2C12 cells,
and Notch mutants lacking the RBP-Jk binding site and the
FIG. 5. RK-BARF0 induces the translocation of unprocessed Notch4 to the nucleus. Stable cell clones containing FLAG/His6 epitope-tagged
RK-BARF0 or pMEP4 expression plasmids were transiently transfected with Notch4-myc and treated for 24 h with 8 mM CdCl2 or left untreated.
Protein (40 mg) of whole-cell lysates (A) and 7 or 23 mg of nuclear lysates (B) were subjected to SDS-PAGE and analyzed for the presence of
Notch4-myc by using anti-myc (9E10) antibody.
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Notch NLS can still activate transcription (31). Notch4 is fre-
quently rearranged by mouse mammary tumor virus integra-
tion, and Notch gene family members are activated through
chromosomal translocations. In human tumors, novel Notch4
mRNAs have also been identified that contain the intracellular
domain and lack the RBP-Jk binding site (20).
Multiple potential ORFs are formed by the differentially
spliced BamHI A mRNAs; however, the proteins encoded by
the RNAs remain unidentified. The most abundant 4.8-kb
mRNA was originally predicted to have the structure found in
the RB2 cDNA, and the two largest ORFs identified in this
cDNA are the RK103 ORF and the RB2 ORF (37). A recent
report has confirmed the splice donor and acceptor sites de-
scribed in the RB2 cDNA. The data indicate that the RB2
ORF is identical to an ORF identified in the A73 cDNA and
that the RPMS1 ORF, originally described in the C22.2 cDNA,
is identical to the RK103 ORF (37, 40). These ORFs encode
proteins when expressed with a recombinant epitope tag, and
A
FIG. 6. RK-BARF0 is expressed in the ER and can be secreted. (A) Stable H1299 cell lines containing FLAG/His6-tagged RK-BARF0 were
induced by 5 mM CdCl2 to express RK-BARF0, and cells were stained 2 and 4 h postinduction with anti-FLAG antibody and FITC-conjugated
anti-mouse antibody to determine RK-BARF0 localization. (B) Culture medium (8 ml/5 3 106 cells) of induced P3HR1 cells containing FLAG/
His6-tagged RK-BARF0, RK1–179, RK1–158, or pMEP4 expression plasmids was incubated with anti-FLAG M2 beads. Immunoprecipitates (I.P.)
from culture medium and 50 mg of protein of whole-cell lysates were subjected to SDS-PAGE. FLAG/His6-tagged RK-BARF0, RK1–179, or RK1–
158 were detected with the anti-His- probe polyclonal antibody. Solid arrows indicate the protein bands which are identified in both whole-cell
lysate and cell culture media; open arrows indicate the protein bands which are present only in the cell culture media. D.L., direct load; WB,
Western blot.
FIG. 7. RK-BARF0 induces LMP1 expression in EBNA2-negative
P3HR1 cells. Stable cell lines containing FLAG/His6-tagged RK-
BARF0, RK1–158, or pMEP4 expression plasmids were treated for
48 h with 1.5 mM CdCl2. (A) Immunoblot analysis of 80 mg of protein
of whole-cell lysates with an anti-His-probe to identify RK-BARF0 and
RK1–158. (B) Immunoblot analysis of 60 mg of protein of whole-cell
lysates by anti-LMP1 (CS1-4) to identify LMP1. WB, Western blot.
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potential interacting proteins have been identified using the
yeast two hybrid. Interestingly, RPMS1 also interacts with
RBP-Jk and negatively regulates a synthetic promoter con-
taining four copies of the EBNA2-responsive element of the
BamHI C promoter (40).
Clearly, these ORFs can encode proteins that have interest-
ing biologic properties; however, antisera that specifically rec-
ognize the RPMS1 or RB2 protein products have not yet been
produced. A previously described rabbit antiserum produced
using a BARF0-specific peptide was shown to identify a gluta-
thione S-transferase–BARF0 fusion protein, in vitro-translated
RK-BARF0, and transfected RK-BARF0 (10). This antiserum
was subsequently shown to also react with a cellular protein
that was expressed at high levels in the EBV-negative Burkitt’s
lymphoma cell line DG75 and other EBV-negative B-cell lines
(24). This cellular protein was identical in size to transfected
RK-BARF0 and obscured the detection of the authentic pro-
tein in EBV-infected cells or tissues. In this study, the anti-
serum was affinity purified using the BARF0 peptide to reduce
reactivity with the cellular protein and the interaction between
Notch and RK-BARF0 was analyzed. The detection of unproc-
essed Notch4 in the complexes immunoprecipitated from the
EBV-positive Raji cell line but not from the-EBV negative
DG75 cell line provides indirect evidence for the expression of
RK-BARF0.
The direct interaction of RK-BARF0 with Notch provides
another mechanism through which EBV affects or usurps the
Notch signaling pathway. The protein product of the RK-
BARF0 ORF is the first viral protein that has been shown to
interact with Notch and affect its intracellular location. The
interaction of several EBV proteins with components of the
Notch signaling pathway highlights the multiple mechanisms
that regulate this pathway and affect cellular and viral gene
expression and growth control.
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